Fei Yu
Impact in
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- RNA Interference and Gene Delivery 14
- Advanced biosensing and bioanalysis techniques 7
- Epigenetics and DNA Methylation 6
- RNA modifications and cancer 5
- Oncology 22
- Chemokine receptors and signaling 5
- Co-authors
- David Oupický (18 shared papers)Jing Li (11 shared papers)Ying Xie (7 shared papers)Chengzhi Cai (5 shared papers)Xiao Dong Chen (3 shared papers)Zhenqing Hou (4 shared papers)Jiahong Dong (3 shared papers)Wei Rui (1 shared paper)
- Journals
- Journal of Controlled Release (5 papers)International Journal of Pharmaceutics (4 papers)Frontiers in Immunology (3 papers)Acta Biomaterialia (3 papers)Chemical Engineering Journal (2 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Fei Yu
88 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 137
- Pharmaceutical Science 202
- Biomaterials 363
- Molecular Biology 992
- Molecular Medicine 68
- Oncology 370
Countries citing papers authored by Fei Yu
This map shows the geographic impact of Fei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Yu more than expected).
Fields of papers citing papers by Fei Yu
This network shows the impact of papers produced by Fei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Yu. The network helps show where Fei Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 158 | |
| 2 | 2016 | 122 | |
| 3 | 2017 | 98 | |
| 4 | 2015 | 88 | |
| 5 | 2016 | 84 | |
| 6 | 2016 | 82 | |
| 7 | 2011 | 72 | |
| 8 | 2015 | 71 | |
| 9 | 2015 | 65 | |
| 10 | 2010 | 64 | |
| 11 | 2018 | 60 | |
| 12 | 2004 | 54 | |
| 13 | 2017 | 53 | |
| 14 | 2018 | 50 | |
| 15 | 2022 | 48 | |
| 16 | 2017 | 47 | |
| 17 | 2018 | 35 | |
| 18 | 2016 | 34 | |
| 19 | 2021 | 34 | |
| 20 | 2021 | 33 |
About Fei Yu
Fei Yu is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Pulmonary and Respiratory Medicine and Biomaterials, having authored 92 papers that have together received 2.2k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (14 papers), Nanoparticle-Based Drug Delivery (8 papers), Advanced biosensing and bioanalysis techniques (7 papers), Epigenetics and DNA Methylation (6 papers), Click Chemistry and Applications (5 papers), RNA modifications and cancer (5 papers), Chemokine receptors and signaling (5 papers) and Cancer-related molecular mechanisms research (5 papers). The work is most often cited by research in Pharmaceutical Science (202 citations), Biomaterials (363 citations), Molecular Biology (992 citations), Molecular Medicine (68 citations) and Oncology (370 citations). Fei Yu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include David Oupický, Jing Li, Ying Xie, Chengzhi Cai, Xiao Dong Chen, Zhenqing Hou, Jiahong Dong, Wei Rui, Guangna Liu and Xin Lin. Their work appears in journals such as Journal of Controlled Release, International Journal of Pharmaceutics, Frontiers in Immunology, Acta Biomaterialia and Chemical Engineering Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.